Dowling & Yahnke LLC Cuts Stake in DexCom, Inc. (DXCM)

Share on StockTwits

Dowling & Yahnke LLC decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 7.8% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,956 shares of the medical device company’s stock after selling 4,899 shares during the period. Dowling & Yahnke LLC owned approximately 0.07% of DexCom worth $8,290,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Waddell & Reed Financial Inc. boosted its stake in shares of DexCom by 164.8% in the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock valued at $54,075,000 after purchasing an additional 354,331 shares in the last quarter. UBS Group AG boosted its stake in shares of DexCom by 76.3% in the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after purchasing an additional 6,890 shares in the last quarter. BlackRock Inc. boosted its stake in shares of DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock valued at $390,978,000 after purchasing an additional 228,933 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of DexCom by 14.4% in the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock valued at $22,448,000 after purchasing an additional 29,825 shares in the last quarter. Finally, Federated Investors Inc. PA boosted its stake in shares of DexCom by 97.1% in the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock valued at $43,710,000 after purchasing an additional 226,740 shares in the last quarter.

NASDAQ:DXCM opened at $125.41 on Wednesday. DexCom, Inc. has a 52 week low of $44.50 and a 52 week high of $148.56. The company has a debt-to-equity ratio of 0.69, a current ratio of 4.89 and a quick ratio of 4.62. The firm has a market cap of $11.08 billion, a P/E ratio of -216.22 and a beta of 0.47.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The company had revenue of $242.50 million during the quarter, compared to analyst estimates of $205.81 million. During the same period in the prior year, the business posted ($0.16) EPS. The firm’s revenue was up 42.1% compared to the same quarter last year. Equities research analysts expect that DexCom, Inc. will post -0.47 EPS for the current fiscal year.

In other DexCom news, EVP Steven Robert Pacelli sold 3,114 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $139.96, for a total value of $435,835.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew K. Balo sold 5,000 shares of the company’s stock in a transaction on Friday, September 14th. The stock was sold at an average price of $145.17, for a total transaction of $725,850.00. The disclosure for this sale can be found here. Insiders have sold a total of 182,692 shares of company stock valued at $24,908,639 over the last quarter. 1.80% of the stock is currently owned by company insiders.

DXCM has been the subject of a number of research reports. BMO Capital Markets upped their price objective on shares of DexCom to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, July 10th. ValuEngine raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 11th. BidaskClub cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Piper Jaffray Companies upped their price objective on shares of DexCom to $150.00 and gave the company an “overweight” rating in a research note on Thursday, August 2nd. Finally, Oppenheimer set a $125.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Thursday, August 2nd. Eight analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $129.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply